

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – September 10, 2014 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
 - A. July 9, 2014 DUR Minutes – Vote
 - B. July 9, 2014 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 4. Update on Medication Coverage Authorization Unit/Drug Utilization Review of Prenatal Vitamins – See Appendix B**
 - A. Medication Coverage Activity for July 2014
 - B. Pharmacy Help Desk Activity for July 2014
 - C. Drug Utilization Review of Prenatal Vitamins

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 5. Action Item – Vote to Prior Authorize Zohydro™ ER (Hydrocodone Bitartrate) and Xartemis™ XR (Oxycodone/Acetaminophen) – See Appendix C**
 - A. COP Recommendations

Items to be presented by Dr. Anderson, Dr. Muchmore, Chairman:

- 6. Action Item – Vote to Prior Authorize Zontivity™ (Vorapaxar) – See Appendix D**
 - A. COP Recommendations

Items to be presented by Dr. Anderson, Dr. Muchmore, Chairman:

- 7. Action Item – Annual Review of Synagis® (Palivizumab) – See Appendix E**
 - A. Current Prior Authorization Criteria
 - B. Utilization of Synagis®
 - C. Prior Authorization of Synagis®
 - D. Market News and Updates
 - E. COP Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 8. Annual Review of Atypical Antipsychotics and 30-Day Notice to Prior Authorize Versacloz™ (Clozapine Oral Suspension) – See Appendix F**
 - A. Current Tier Structure
 - B. Utilization of Atypical Antipsychotics
 - C. Prior Authorization of Atypical Antipsychotics
 - D. Atypical Antipsychotic Utilization Trends
 - E. Market News and Updates
 - F. COP Recommendations
 - G. Utilization Details

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 9. Action Item – Annual Review of ADHD and Narcolepsy Medications – See Appendix G**
 - A. Current Prior Authorization Criteria
 - B. Utilization of ADHD & Narcolepsy Medications
 - C. Prior Authorization of ADHD & Narcolepsy Medications
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Utilization Details

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 10. 30-Day Notice to Prior Authorize Grastek® (Timothy Grass Pollen Allergen Extract) and Ragwitek™ (Short Ragweed Pollen Allergen Extract) – See Appendix H**
 - A. Introduction
 - B. Product Summaries
 - C. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

- 11. FDA and DEA Updates – See Appendix I**

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

- 12. Future Business**
 - A. Annual Reviews
 - B. New Product Reviews

Items to be presented by Dr. Muchmore, Chairman:

- 13. Adjournment**